Abstract
Treatment of kidney cancer represents an open challenge for scientists and clinicians. In fact,renal tumours are resistant to virtually all of the currently available chemotherapeutics, beingonly partially sensitive to immunological agents. During the last decade, knowledge of geneticbasis of cancer has grown considerably. This has lead to an authentic revolution in the clinicalmanagement of renal tumours: the introduction of targeted therapies. Novel agents addressangiogenic signalling pathways through inhibition of the vascular endothelial growth factor(VEGF) or the mammalian target of rapamycin (mTOR). However, there is still no greatevidence favouring one drug over the others. This underlines the need for decision-making toolsin renal cell cancer treatment, in order to rationalise the choice of appropriate targeted agentsand to enable individualised clinical management. This is a brief overview on the state of theart of the treatment of metastatic renal tumour.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
